Advancis drug fails again

Advancis Pharmaceutical said that its lead product, a once-a-day version of the widely used antibiotic amoxicillin, has failed testing for a second time. In its study of its drug in children with strep throat, it was only 65.3 percent successful, far less than the 85 percent needed to qualify as a primary treatment. Standard penicillin worked better. Advancis has about $40 million in cash and could afford more testing, but company executives said they will have to take a critical look at whether it is worth the risk.

- read this article from The Washington Post for more 

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.